ARIX.L Regulatory News (ARIX)

Board Committee Changes

LONDON, 31 MARCH 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces changes to the membership of its Board's Audit Committee.

David U'Prichard, a non-executive director, has been appointed a member of the Audit Committee with immediate effect.

Following this addition, the membership of the Board's Audit Committee is as follows:

Sir John Banham, Chair

Lord Hutton of Furness

David U'Prichard

ENDS

For more information, please contact:

Arix Bioscience PLC

Joe Anderson, CEO

+44 (0) 20 7290 1052

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com